|
1
|
Liotta LA: Tumor invasion and metastasis:
role of the extracellular matrix. Cancer Res. 46:1–7.
1986.PubMed/NCBI
|
|
2
|
Chuang CK and Liao SK: Differential
expression of CD44 variant isoforms by cell lines and tissue
specimens of transitional cell carcinoma. Anticancer Res.
23:4635–4640. 2003.PubMed/NCBI
|
|
3
|
Brown PD, Levy AT, Margulies IMK, Liotta
LA and Stetler-Stevenson WG: Independent expression and cellular
processing of Mr 72,000 type IV collagenase and interstitial
collagenase in human tumorigenic cell lines. Cancer Res.
50:6184–6191. 1990.PubMed/NCBI
|
|
4
|
Fleshner NE, Herr HW, Stewart AK, Murphy
GP, Mettline C and Menck HR: The national cancer data base report
on bladder carcinoma. Cancer. 77:1505–1513. 1996. View Article : Google Scholar
|
|
5
|
Chuang CK and Liao SK: Evaluation of
CA19-9 as a tumor marker in urothelial malignancy. Scand J Urol
Nephrol. 38:359–365. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liotta LA, Tryggvason K, Garbisa S, Hart
I, Foltz CM and Shafie S: Metastatic potential correlates with
enzymatic degradation of basement membrane collagen. Nature.
284:67–68. 1980. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Koivunen E, Ristimaki A, Itkonen O, Osman
S, Vuento M and Stenman UH: Tumor-associated trypsin participates
in cancer cell mediated defradation of extracellular matrix. Cancer
Res. 51:2107–2112. 1991.PubMed/NCBI
|
|
8
|
Van Wart HE and Birkedal-Hansen H: The
cysteine switch: a principle of regulation of metalloproteinase
activity with potential applicability to the entire matrix
metalloproteinase gene family. Proc Natl Acad Sci USA.
87:5578–5582. 1990.PubMed/NCBI
|
|
9
|
Mignatti P and Rifkin DB: Biology and
biochemistry of proteinases in tumor invasion. Physiol Rev.
73:161–195. 1993.PubMed/NCBI
|
|
10
|
Liu BCS and Liotta LA: Biochemistry of
bladder cancer invasion and metastasis: clinical implications. Urol
Clin North Am. 19:621–627. 1992.PubMed/NCBI
|
|
11
|
Redwood SM, Liu BCS, Weiss RE, Hodge DE
and Droller MJ: Abrogation of the invasion of human bladder tumor
cells by using protease inhibitor(s). Cancer. 69:1212–1219. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liotta LA and Stetler-Stevenson WG: Tumor
invasion and metastasis: an imbalance of positive and negative
regulation. Cancer Res. 51:5054–5059. 1991.PubMed/NCBI
|
|
13
|
Agnes N, Maud J and Erik M: Matrix
metalloproteinases at cancer tumor-host interface. Semin Cell Dev
Biol. 19:52–60. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kitagawa Y, Kunimi K, Ito H, et al:
Expression and tissue localization of membrane-types 1, 2 and 3
matrix metalloproteinases in human urothelial carcinomas. J Urol.
160:1540–1545. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakajima M, Welch DR, Belloni PN and
Nicolson GL: Degradation and basement membrane type IV collagen and
lung subendotherial matrix by rat mammary adenocarcinoma cell
clones of differing metastatic potentials. Cancer Res.
47:4869–4876. 1987.PubMed/NCBI
|
|
16
|
Nakajima M, Welch DR, Wynn DM, Tsuruo T
and Nicolson GL: Serum and plasma Mr 92,000 progelatinase levels
correlate with spontaneous metastasis of rat 13762NF mammary
adenocarcinoma. Cancer Res. 53:5802–5807. 1993.PubMed/NCBI
|
|
17
|
Pyke C, Ralfkiaer E, Tryggvason K and Dano
K: Messenger RNA for two type IV collagenases is located in stromal
cells in human colon cancer. Am J Pathol. 142:359–365.
1993.PubMed/NCBI
|
|
18
|
Stearns ME and Wang M: Type IV collagenase
(Mr 72,000) expression in human prostate: benign and malignant
tissue. Cancer Res. 53:878–883. 1993.PubMed/NCBI
|
|
19
|
Kanayama HO, Yokota KY, Kurokawa Y,
Murakami Y, Nishitani M and Kagawa S: Prognostic values of matrix
metalloproteinase-2 and tissue inhibitor of metalloproteinase-2
expression in bladder cancer. Cancer. 82:1359–1366. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Grignon DJ, Sakr W, Toth M, et al: High
levels of tissue inhibitor of metalloproteinase-2 (TIMP-2)
expression are associated with poor outcome in invasive bladder
cancer. Cancer Res. 56:1654–1659. 1996.PubMed/NCBI
|
|
21
|
Hanahan D and Folkman J: Patterns and
emerging mechanisms of the angiogenic switch during tumorigenesis.
Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Davis B, Waxman J, Wasan H, et al: Levels
of matrix metalloproteinase in bladder cancer correlate with tumor
grade and invasion. Cancer Res. 53:5365–5369. 1993.PubMed/NCBI
|
|
23
|
Gerhards S, Jung K, Koenig F, et al:
Excretion of matrix metalloproteinases 2 and 9 in urine is
associated with a high stage and grade of bladder carcinoma.
Urology. 57:675–679. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cawston TE, Galloway WA, Mercer E, Murphy
G and Reynolds JJ: Purification of rabbit bone inhibitor for
collagenase. Biochem J. 195:159–165. 1981.PubMed/NCBI
|
|
25
|
Docherty AJ, Lyons A, Smith BJ, et al:
Sequence of human tissue inhibitor of metalloproteinases and its
identity to erythroid-potentiating activity. Nature. 318:66–69.
1985. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mignatti P, Robbins E and Rifkin DB: Tumor
invasion through the human amniotic membrane: requirement for a
proteinase cascade. Cell. 47:487–498. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schultz RM, Silberman S, Persky B,
Bajkowski AS and Carmichael DF: Inhibition by human recombinant
tissue inhibitor of metalloproteinases of human amnion invasion and
lung colonization by murine B16–F10 melanoma cells. Cancer Res.
48:5539–5545. 1988.PubMed/NCBI
|
|
28
|
Alvarez OA, Carmichael DF and DeClerck YA:
Inhibition of collagenolytic activity and metastasis of tumor cells
by a recombinant human tissue inhititor of metalloproteinases. J
Natl Cancer Inst. 82:589–595. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stetler-Stevenson WG, Krutzsch HC and
Liotta LA: TIMP2: identification and characterization of a new
member of the metalloproteinases inhibitor family. Matrix
Supplement. 1:299–306. 1992.PubMed/NCBI
|
|
30
|
Denhardt DT, Khokha R, Yagel S, Overall CM
and Parhar RS: Oncogenic consequences of down-regulating TIMP
expression in 3T3 cells with antisense RNA. Matrix Supplement.
1:281–285. 1992.PubMed/NCBI
|
|
31
|
Baker EA, Stephenson TJ, Reed MW and Brown
NJ: Expression of proteinases and inhibitors in human breast cancer
progression and survival. Mol Pathol. 55:300–304. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Takahashi K, Eto H and Tanabe KK:
Involvement of CD44 in matrix metalloproteinase-2 regulation in
human melanoma cells. Int J Cancer. 29:387–395. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Isacke CM and Yarwood H: Molecules in
focus. The hyaluronan receptor, CD44. Int J Biochem B. 34:718–721.
2002. View Article : Google Scholar
|
